<DOC>
	<DOCNO>NCT02477345</DOCNO>
	<brief_summary>This protocol involve compassionate use intravenous fish oil infusion , Omegaven . The protocol involve infant child parenteral nutrition-associated liver disease enable reversal elevate serum liver enzyme direct bilirubin ( cholestasis ) .</brief_summary>
	<brief_title>Compassionate Use Omegaven IV Fat Emulsion</brief_title>
	<detailed_description>In United States , patient dependent upon parenteral nutrition ( PN ) receive parenteral fat emulsion compose soybean oil . Lipids necessary PN dependent patient due high caloric value essential fatty acid content . Intravenous lipid emulsion implicate predispose patient PN associate liver disease . Phytosterols contain soybean oil think deleterious effect biliary secretion . Accumulation lipids hepatic Kupffer cell may impair liver function . Omega 6 fatty acid emulsion prevent fatty acid emulsion prevent fatty acid deficiency , think clear manner similar enteral chylomicron therefore accumulate liver result steatotic liver injury ( neonatal cholestasis ) . It hypothesize fat emulsion comprise omega 3 fatty acid ( i.e . : fish oil ) , de novo lipogenesis , reduction arachidonic acid-derived inflammatory mediator , prevention essential fatty acid deficiency presence small amount arachidonic acid , improve clearance lipid serum . Animal study show IV fat emulsion fish oil high eicosapentaenic docosahexaenoic acid reduce impairment bile flow see cholestasis cause conventional fat emulsion . Furthermore , intravenous omega-e fatty acid well tolerate might reduce hepatic dysfunction . By administer Omegaven place conventional phytosterol/soybean fat emulsion , progression PN-associated cholestasis prevent reverse .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>subject infant child birth 5 year age diagnosis parenteral nutrition associate liver disease ( PNALD ) ( define two consecutive direct bilirubin level 2 mg/dl ) parenteral nutritiondependent infant child . subject must utilized standard therapy prevent progression cholestasis include reduction/removal copper manganese daily PN , trial enteral feeding possible , use ursodiol and/or phenobarbital . patient exclude documented cause chronic liver disease ( i.e . : Hepatitis C , cystic fibrosis , biliary atresia , alpha1antitrypsin deficiency ) , already sign proven severe advanced liver disease include cirrhosis biopsy , varix , ascites . Additional exclusion criterion : active coagulopathy characterize ongoing bleeding requirement clot factor replacement ( e.g . fresh frozen plasma cryoprecipitate ) maintain homeostasis impaired lipid metabolism severe hyperlipidemia without pancreatitis unstable diabetes mellitus hyperglycemia stroke , embolism collapse shock recent myocardial infarction ( MI ) cholestasis due reason parenteral nutrition associate cholestasis ( PNAC ) active new infection time initiation Omegaven hemodynamic instability patient enrol clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cholestasis</keyword>
	<keyword>Parenteral Nutrition</keyword>
	<keyword>Liver disease</keyword>
</DOC>